Scilex Holding (SCLX) Total Debt (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Total Debt of $80.8 million for Q1 2026, up 104.81% year-over-year from $39.4 million in Q1 2025, and down 23.6% on a QoQ basis from $105.7 million in Q4 2025.
Scilex Holding (SCLX) Total Debt (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Total Debt for 6 consecutive years, with $80.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt rose 104.81% year-over-year to $80.8 million; the TTM figure through Mar 2026 stood at $80.8 million (up 104.81% YoY), while the FY2025 annual figure was $105.7 million, up 196.02% from the prior year.
- Total Debt came in at $80.8 million for Q1 2026 at Scilex Holding, down from $105.7 million in the prior quarter.
- The five-year high for Total Debt was $125.5 million in Q4 2023, with the low at $2.0 million in Q2 2022.
- Average Total Debt over 5 years is $66.3 million, with a median of $63.2 million recorded in 2025.
- Across the five-year window, Total Debt jumped 4010.62% in 2023 and tumbled 71.53% in 2024, its largest moves.
- Year by year, Total Debt stood at $3.0 million in 2022, then soared by 4122.11% to $125.5 million in 2023, then slumped by 71.53% to $35.7 million in 2024, then surged by 196.02% to $105.7 million in 2025, then declined by 23.6% to $80.8 million in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $80.8 million, $105.7 million, and $45.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 43.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 54.99 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 64.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -24.45 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -19.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 80.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.78 Mn |
| Dec 31, 2025 | 105.74 Mn |
| Sep 30, 2025 | 45.67 Mn |
| Jun 30, 2025 | 39.87 Mn |
| Mar 31, 2025 | 39.44 Mn |
| Dec 31, 2024 | 35.72 Mn |
| Sep 30, 2024 | 98.97 Mn |
| Jun 30, 2024 | 104.40 Mn |
| Mar 31, 2024 | 109.25 Mn |
| Dec 31, 2023 | 125.47 Mn |
| Sep 30, 2023 | 122.15 Mn |
| Jun 30, 2023 | 15.92 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Dec 31, 2021 | 109.99 Mn |